Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 354

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY

Open access
Cosgrove, A. P., Corry, I. S., Graham, H. K.·1994·Developmental Medicine & Child Neurology

Abstract

SUMMARY: The role of intramuscular botulinum toxin A in the treatment of 26 children with cerebral palsy was evaluated. The indication for injection was the presence of a dynamic contracture of lower‐limb muscles interfering with positioning or walking. Spastic target muscles were identified by clinical examination and, in ambulant children, by gait analysis. Between 50 and 320 units of botulinum toxin were injected into each muscle group to a total dose of 100 to 400 units per child. The effects of injection were monitored by repeated clinical examination and gait analysis. There were no clinically detectable systemic side‐effects, and all but one patient had a reduction in tone, which occurred within three days and persisted for two to four months. There were significant improvements in ambulatory status and in sagittal‐plane kinematics. In some cases these gains persisted after the tone‐reducing effects of the toxin had worn off. RÉSUMÉ: La toxine boiulinique dans le iraiiemenl de ľIMC au niveau des membres inférieurs Ľaction dc la toxine botulinique A en intramusculaire a étéévaluée chez 26 enfants IMC. Ľindication de ľinjection était la presence de contractions dynamiques des muscles du membre inférieur perturbant la station‐locomotion. Les cibles musculaires spastiques furent identifiées par ľexamen clinique et par ľanalyse de la démarche chez les enfants marchant. Entre 50 et 320 unités de toxine botulinique ont été injectées dans chaque groupe musculaire avec une dose totale de 100 a 400 unités par enfant. Les effets de ľinjection ont été contrôlés par des examens cliniques répétés et une analyse de la demarche. II n'a été découvert cliniquement aucun effet secondaire, et chez tous les patients sauf un, il a été observe une diminution du tonus, survenant au bout de trois jours et durant de deux à quatre mois. II fut noté des améliorations significatives dans ľallure de la démarche et dans la cinematique du plan sagittal. Dans quelques cas, les améliorations ont persiste alors même que les effets de réduction de tonus de la toxine avaient disparu. ZUSAMMENFASSUNG: Botulinum Toxin zur Behandlung der unteren Extremitát bei Cerebralparese Bei 26 Kindern mit Cerebralparese wurde die Wirkung von intramuskulär injiziertem Botulinum Toxin A untersucht. Die Indikation fúr die Injektion war eine dynamische Kontraktur der Beinmuskeln, wodurch Lagerung oder Laufen beeinträchtigt waren. Die spastischen Zielmuskeln wurden durch klinische Untersuchungen und bei gehfähigen Patienten durch Ganganalysen identifiziert. In jede Muskelgruppe wurden 50 bis 320 E Botulinum Toxin injiziert, bis zu einer Gesamtdosis von 100 bis 400 E pro Kind. Die Wirkung der Injektionen wurde durch wiederholte klinische Untersuchungen und Ganganalysen überwacht. Es fanden sich keine klinisch manifesten Nebenwirkungen und bei alien Patienten, außer einem, konnte eine Tonusverminderung festgestellt werden, die innerhalß von drei Tagen auftrat und zwei bis vier Monate anhielt. Es fanden sich signifikante Besserungen der Gehfähigkeit und der sagittalen planen Kinematik. Bei einigen Patienten hielten diese Besserungen weiter an, nachdem die Tonus reduzierende Wirkung des Toxins abgeklungen war. RESUMEN: Toxina botulínica en el manejo de la extremidad inferior en la parálisis infantile Se evaluó el papel de la toxina botulinica A por via intramuscular en 26 niños con parálisis cerebral. La indicación para la inyección era la presencia de una contractura dinámica de los músculos de la extremidad inferior que interferia con la postura y la marcha. Los músculos espásticos implicados fueron escogidos por examen clinico y, en niños que andaban, por análisis de la marcha. En cada grupo muscular se inyectaron entre 50 y 320 unidades de toxina botulinica con una dosis total de 100 a 400 unidades por niño. El efecto de la inyección fue monitorizado por exámenes clinicos repetidos y análisis de la marcha. No hubo ningun efecto secundario detectable clinicamente, todos los pacicntes, excepto uno, tuvierón una reduction del tono muscular que apareció en el curso de tres dias y persistió durante dos a cuatro meses. Hubo una mejoria significativa en la marcha y en la cinética en el plano sagital. En algunos casos estas ganancias persistieron después de que se agotara la actión reductora del tono de la toxina.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1469-8749.1994.tb11864.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 354

Metadata

Authors
Cosgrove, A. P., Corry, I. S., & Graham, H. K.
Venue
Developmental Medicine & Child Neurology
Publisher
Wiley
Published
1994-05
Volume
36
Issue
5
Pages
386-396
ISSN
  • 0012-1622 (ISSN-L)
  • 1469-8749
OpenAlex
W2050083593
Cited by
354
References
8
FWCI
6.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY. https://app.cochat.ai/papers/10.1111/j.1469-8749.1994.tb11864.x
The paper
Cosgrove, A. P., Corry, I. S., & Graham, H. K. (1994). BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.1994.tb11864.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.